書誌事項
- タイトル別名
-
- Guideline for the Treatment of Leprosy by New Quinolones
この論文をさがす
抄録
Ofloxacin(OFLX) is often applied today as a substitution drug of MDT for drug resistance to dapsone, rifampicin or clofazimine. However, OFLX resistance is also becoming a great concern. Low and/or irregular administration are considered to be the major causes of OFLX resistance. OFLX should be used as a combined therapy, and minimal daily dose of 400mg of OFLX or 200 ?? 300mg of levofloxacin is required. Quinolone resistance should be considered when no improvement of clinical and/or bacterial index is observed after the treatment for 6 months. In such cases, resistance gene detection is necessary.
収録刊行物
-
- 日本ハンセン病学会雑誌
-
日本ハンセン病学会雑誌 73 (1), 65-67, 2004
日本ハンセン病学会
- Tweet
キーワード
詳細情報
-
- CRID
- 1390282681300137984
-
- NII論文ID
- 10012123039
-
- NII書誌ID
- AN10559906
-
- COI
- 1:STN:280:DC%2BD2c7kt1Gnsw%3D%3D
-
- ISSN
- 1884314X
- 13423681
-
- PubMed
- 15035068
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可